Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: Oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury

Circulation

Volumn 96, Issue 3, 1997, Pages 949-958

  Cook, Jacquelynn J ^a   Glass, Joan D ^a   Sitko, Gary R ^a   Holahan, Marie A ^a   Stupienski III, Raymond F ^a   Wallace, Audrey A ^a   Stump, Gary L ^a   Hand, Elizabeth L ^a   Askew, Ben C ^a   Hartman, George D ^a   Gould, Robert J ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Coronary disease; Myocardial infarction; Platelet aggregation inhibitors; Thromhosis

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; BLEEDING TIME; BLOOD PLATELETS; CORONARY DISEASE; CORONARY THROMBOSIS; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; MALE; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SULFONAMIDES;

EID: 0030840932     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J. 1995;130:877-892.
2. Ojima I, Chakravarty S, Dong Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorgan Med Chem. 1995;3:337-360.
3. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 1995; 130:666-672.
4. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
5. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
6. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol. 1993;22:381-389.
7. Simoons ML, Jan de Boer M, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
8. Harrington RA, Schulman SP, Kleiman NS, Lincoff AM, Goldschmidt-Clermont PJ, Joseph D, Sigmon KN, Parker J, Marchant K, Kitt MM. Profound sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation. 1994;90(suppl I):I-232. Abstract.
9. Ohman EM, Kleiman NS, Talley JD, Gacioch G, Navetta FI, Carney RJ, Worley S, Anderson HV, Cohen M, Kereiakes D, Joseph D, Sigmon KN, Topol EJ. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation. 1994;90(suppl I):I-564. Abstract.
10. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, duMee CP, Califf RM, Topol EJ. Multicenter randomized double-blind placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
11. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault J-R, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian lamifiban study. Circulation. 1996;94:899-905.
12. Kereiakes D, Kleiman N, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton J, Weaver SW, McKee D, Sax FL. A dosing study in high-risk PTCA of MK-383, a platelet IIb/IIIa antagonist. Circulation. 1994;90(suppl I):I-21. Abstract.
13. Theroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan L-B, Deschenes N, Fitzpatrick V, Sax FL. A heparin-controlled study of MK-383 in unstable angina. Circulation. 1994;90(suppl I):I-231. Abstract.
14. Askew BC, Bednar B, Bednar RA, Claremon DA, Cook JJ, McIntyre CJ, Hunt CA, Gould RJ, Lynch RJ, Lynch JJ, Gaul SL, Stranieri MT, Sitko GR, Holahan MA, Glass JD, Hamill T, Gorham LM, Prueksaritanont T, Gorham LM, Baldwin JJ, Hartman GD. Non-peptide glycoprotein IIb/IIIa inhibitors: design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. J Med Chem. In press.
15. Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ. 15: Non-peptide glycoprotein IIb/IIIa inhibitors: antithrombotic efficacy of L-738,167, a long acting GP IIb/IIIa antagonist, correlates with inhibition of ADP-induced platelet aggregation but not with bleeding time prolongation. J Pharmacol Exp Ther. 1997;281:677-689.
16. Bednar B, Cunningham ME, McQueney PA, Egbertson MS, Askew BC, Bednar RA, Hartman GD, Gould RJ. Flow cytometric measurement of kinetic and equilibrium binding parameters of RGD ligands in binding to GP IIb/IIIa on platelets. Cytometry: In press.
17. Prueksaritanont T, Gorham LM, Naue JA, Hamill TG, Askew BC, Vyas KP. Disposition of L-738,167, a potent and long acting fibrinogen receptor antagonist, in dogs: dose-dependent pharmacokinetics. Drug Metab Dispos. 1997;25:355-361.
18. Bednar RA, Gaul SL, Cook JJ, Askew BC, Hartman GD, Gould RJ, Bednar B. Novel mechanism for long acting GP IIb/IIIa antagonists. Circulation. 1996;94(suppl I):I-98.
19. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res. 1980;17:841-853.
20. Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF, Wallace AA, Hand EL, Gilbert JD, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ, Lynch JJ. Non-peptide glycoprotein IIb/IIIa inhibitors, 8: antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996;278:62-73.
21. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W. Early phase acute myocardial infarct size quantitation: validation of the triphenyltetrazolium chloride tissue enzyme staining technique. Am Heart J. 1981;101:593-600.
22. Vivaldi MT, Kloner RA, Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol. 1985;121:522-530.
23. Jergens AE, Turrentine MA, Krave KH, Johnson GS. Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocylopenia, uremia, and von Willebrand's disease. Am J Vet Res. 1987;48:1337-1342.
24. Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea pigs and dogs: evidence that Ro 43-8857 is orally active. Thromb Haemost. 1993;70:838-847.
25. Muller TH, Schurer H, Waldmann L, Bauer E, Himmelsbach F, Binder K. Oral activity of BIBU 104, a prodrug of the non-peptide fibrinogen receptor antagonist BIBU 52, in mice and monkeys. Thromb Haemost. 1993;69:975. Abstract.
26. Pike NB, Foster MR, Hornby EJ, Lumley P. Effect of the fibrinogen receptor antagonist GR144053 upon platelet aggregation ex vivo following intravenous and oral administration to the marmoset and cynomolgus monkey. Thromb Haemost. 1993;69:1701. Abstract.
27. Barrett JS, Gould RJ, Ellis JD, Holahan MA, Stranieri MT, Lynch JJ, Hartman GD, Ihle N, Duggan M, Moreno OA, Theoharides AD. Pharmacokinetics and pharmacodynamics of L-703,104, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. Pharm Res. 1994;11:426-431.
28. Demrow H, Batley C, Folts JD. SDZ GPI 562, an oral peptidomimetic inhibitor of the platelet GP IIb/IIIa abolishes epinephrine and shear induced cyclic flow reductions in stenosed monkey carotid arteries. J Am Coll Cardiol. 1995;25:70A. Abstract.
29. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA, Haas NF, King LW, Zablocki JA, Keller BT, Broschat K, Engleman VW, Herin M, Jacqmin P, Feigen LP. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation. 1995;91:403-410.
30. Just M, Hropot M, Jablonka B, Konig W, Stilz HU. Biological characteristics of the new orally active fibrinogen receptor antagonist S 1762. Thromb Haemost. 1995;73:1444. Abstract.
31. Leadley RJ, Bostwick JS, Kasiewski CJ, Chu V, Klein SI, Czekaj M, Gardner CJ, Perrone MH, Dunwiddie CT. Amithrombotic activity of RPR110173, an orally active platelet fibrinogen receptor antagonist, in canine models of arterial thrombosis. Circulation. 1995;92(suppl I):I-488. Abstract.
32. Refino C, Modi N, Bullens S, Pater C, Lipari T, Wu D, Blackburn B, Weller T, Steiner B, Bunting S. Pharmacokinetics and pharmacodynamics of a potent, non-peptidic GP IIb/IIIa receptor antagonist (Ro 44-3888) following oral administration of a prodrug form (Ro 48-3657) to rhesus monkeys. Blood. 1995:80:90a. Abstract.
33. Mousa SA, DeGrado WF, Mu D-X, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa antagonist. Circulation. 1996;93: 537-543.
34. Anders RJ, Alexander JC, Hantsbarger GL, Burns DM, Oliver SD, Cole G, Fitzgerald DJ. Demonstration of potent inhibition of platelet aggregation with an orally active GP IIb/IIIa receptor antagonist. J Am Coll Cordial. 1995;25:117A. Abstract.
35. Kottke-Marchant K, Simpendorfer C, Lowrie M, Burns D, Anders RJ. Sustained but variable inhibition of platelet aggregation with xemlofiban, an oral GP IIb/IIIa receptor antagonist, in patients with unstable angina. Circulation. 1995;92(suppl I):I-488. Abstract.
36. Narjes H, Weisenberger H, Muller TH, Deichsel G, Krause J. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 XX in healthy volunteers. Thromb Haemost. 1995;73:1315. Abstract.
37. Muller TH, Weisenberger H, Brikl R, Kirchner M, Narjes H, Himmelsbach F, Guth B, Krause J. Pharmacodynamics and kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in man. Thromb Haemost. 1995;73:1445. Abstract.